Hantz Financial Services Inc. Has $3.10 Million Stake in Icon Plc $ICLR

Hantz Financial Services Inc. trimmed its holdings in shares of Icon Plc (NASDAQ:ICLR) by 23.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,306 shares of the medical research company’s stock after selling 6,373 shares during the period. Hantz Financial Services Inc.’s holdings in Icon were worth $3,099,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ICLR. SVB Wealth LLC acquired a new stake in Icon during the 1st quarter valued at $28,000. Ameritas Advisory Services LLC acquired a new stake in Icon during the 2nd quarter valued at $48,000. LRI Investments LLC acquired a new stake in Icon during the 2nd quarter valued at $49,000. Blue Trust Inc. increased its stake in shares of Icon by 44.0% in the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after buying an additional 120 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Icon by 40,800.0% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock valued at $59,000 after buying an additional 408 shares during the period. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Stock Up 3.9%

NASDAQ:ICLR opened at $171.82 on Friday. Icon Plc has a 12-month low of $125.10 and a 12-month high of $231.89. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $13.88 billion, a P/E ratio of 23.25, a P/E/G ratio of 3.04 and a beta of 1.23. The stock’s fifty day simple moving average is $178.16 and its 200-day simple moving average is $159.38.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $3.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.03. Icon had a return on equity of 10.58% and a net margin of 7.40%.The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same period last year, the company earned $3.35 EPS. The firm’s revenue was up .6% on a year-over-year basis. Equities research analysts expect that Icon Plc will post 13.38 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Rothschild Redb raised Icon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Truist Financial lifted their target price on Icon from $187.00 to $234.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Mizuho lifted their target price on Icon from $173.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Baird R W raised Icon from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 24th. Finally, Robert W. Baird set a $220.00 target price on Icon in a research note on Friday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Icon has an average rating of “Moderate Buy” and an average price target of $207.14.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.